
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion AS has demonstrated significant progress in its proprietary AI platform, AI-Immunology, with the prediction accuracy of its PIONEER model showing an improvement to 81% in identifying immunogenic neoantigens, bolstering the potential efficacy of its cancer immunotherapy, EVX-01. The latest clinical data highlights a 75% overall response rate (ORR) for EVX-01 in combination with pembrolizumab, reflecting an increase from the previous year's 69% and positioning the company favorably compared to its competitors in the neoantigen cancer vaccine sector. If forthcoming data continues to support these positive trends, it may serve as a catalyst for securing strategic partnerships aimed at advancing Evaxion’s late-stage development and commercialization efforts.
Bears say
Evaxion AS's stock has faced negative market reactions despite strong data updates for its EVX-01 product, which suggests that investor expectations for a definitive indication of EVX-01’s contribution are not being met. This disconnect indicates a potential lack of confidence in the company's ability to deliver clear, convincing progress in their oncology pipeline, which could hinder future stock performance. Additionally, the call to accumulate shares during periods of weakness may reflect broader concerns about the company's financial stability and market position, potentially deterring investors looking for stronger, more consistent growth indicators.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares